Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Irinotecan hydrochloride by Edison Oncology Holding for Hepatic (Liver) Tumor: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Hepatic (Liver) Tumor. According...
Irinotecan hydrochloride by Edison Oncology Holding for Ewing Sarcoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Ewing Sarcoma. According to...
Irinotecan hydrochloride by Edison Oncology Holding for Medulloblastoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Medulloblastoma. According to GlobalData,...
Irinotecan hydrochloride by Edison Oncology Holding for Neuroblastoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Neuroblastoma. According to GlobalData,...
Irinotecan hydrochloride by Edison Oncology Holding for Rhabdomyosarcoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Rhabdomyosarcoma. According to GlobalData,...